# China NMPA Product Recall - Implantable cardioverter defibrillator

Source: https://www.keypedia.com/records/china_product_recall/biotronik-se-co-kg-a-european-joint-venture-company/112a1533-e2e9-42a1-bfd6-d1ac4bbddf41
Source feed: China

> China NMPA product recall for Implantable cardioverter defibrillator by BIOTRONIK SE & Co. KG, a European joint venture company published December 04, 2020. Recall level: Level 1 Recall. On December 4, 2020, the National Medical Products Administration (NMPA) announced a voluntary Class

---

## Details

- Record Type: CHINA_PRODUCT_RECALL
- Title: BIOTRONIK SE & Co. KG, a European joint venture, is voluntarily recalling its implantable cardioverter defibrillators.
- Company Name: BIOTRONIK SE & Co. KG, a European joint venture company
- Publication Date: 2020-12-04
- Product Name: Implantable cardioverter defibrillator
- Recall Level: Level 1 Recall
- Recall Reason: A potential problem with the product's battery could cause the battery in certain batches to deplete rapidly, potentially leading to the defibrillator suddenly stopping treatment without warning.
- Discovering Company: Baiduli (Beijing) Medical Devices Co., Ltd.
- Manufacturing Company: BIOTRONIK SE & Co. KG, a European joint venture company
- Summary: On December 4, 2020, the National Medical Products Administration (NMPA) announced a voluntary Class I recall initiated by BIOTRONIK SE & Co. KG concerning its implantable cardioverter-defibrillators. The recall was prompted by a report from a battery manufacturer indicating a potential issue where batteries in specific product batches could deplete rapidly. This critical defect could result in the defibrillator device abruptly ceasing its therapeutic function without warning, posing a serious risk to patient health. BIOTRONIK (Beijing) Medical Devices Co., Ltd., the local entity, reported the issue, leading to the manufacturer's decision to recall the affected devices (Registration Certificate No.: 20193120121). The Class I designation signifies that the use of or exposure to these defective products carries a reasonable probability of causing serious adverse health consequences or even death. The required action involves the active removal of these potentially faulty medical devices from the market to mitigate patient harm, with detailed product information available in an accompanying recall event report form. This proactive measure underscores the company's commitment to patient safety and adherence to regulatory standards under the NMPA's oversight.

Company: https://www.keypedia.com/companies/biotronik-se-co-kg-a-european-joint-venture-company/370e3606-8999-4a27-bc07-fd47b2f7292d